Today: 21 May 2026
Salesforce stock climbs as RBC lifts target to $290, putting AI demand back in play

Salesforce stock climbs as RBC lifts target to $290, putting AI demand back in play

New York, Jan 6, 2026, 20:52 EST — Market closed

  • Salesforce shares rose 2.6% to $262.90 on Tuesday, among the Dow’s stronger performers.
  • RBC Capital raised its price target to $290, arguing enterprise AI tailwinds should show up more clearly in 2026.
  • Investors are watching Friday’s U.S. jobs report for the next read on rates and risk appetite.

Salesforce Inc (CRM) shares rose 2.6% on Tuesday to $262.90, making it one of the better performers on the Dow Jones Industrial Average as U.S. stocks ended higher. The Dow gained about 1% on the day.

The bounce comes as investors test whether high-multiple enterprise software can steady after a shaky start to the year, when concerns about monetizing new AI features weighed on several names. Salesforce trades at about 34 times trailing earnings — a price-to-earnings ratio, which compares a company’s share price to its past profit.

RBC Capital analyst Rishi Jaluria on Monday raised his price target on Salesforce to $290 from $250 and kept a “Sector Perform” rating, a roughly neutral call. Jaluria wrote that 2026 may be the year “AI tailwinds become more evident” for vendors positioned for enterprise adoption, even as some peers stay stuck in the “AI is the death of software” debate. TipRanks

Tuesday’s move also tracked a broader risk-on session in U.S. equities, with gains in heavyweight stocks lifting the Dow by nearly 500 points at one stage and putting upward pressure on several big index components, including Salesforce.

Rate expectations remain a key swing factor for software valuations, and Fed commentary has kept traders alert. Richmond Fed President Tom Barkin said policymakers need to fine-tune rate moves as inflation and labor-market risks persist, with rates now around a “neutral” zone after a December cut. Reuters

Salesforce traded between $255.00 and $263.55 on Tuesday and finished near the top of that range, after opening at $255.20. Traders often treat the day’s low as a near-term support marker, while the stock’s next test sits around the recent highs in the low $260s.

The company’s most recent results in December kept the focus on whether AI features can lift bookings and renewals, even as customers scrutinize spending. Salesforce raised fiscal 2026 revenue guidance to $41.45 billion to $41.55 billion with its third-quarter report, and Chief Executive Marc Benioff pointed to momentum in its Agentforce and Data 360 offerings.

The next major company catalyst is its quarterly report. Nasdaq lists Feb. 25 as an estimated earnings date for Salesforce, though the timing can shift; investors will be watching demand signals such as contracted backlog, margins and any update on AI product uptake.

But the downside case remains straightforward: if customers resist paying for AI add-ons or spending tightens again, the sector’s valuation debate can return quickly. Adobe has already faced fresh skepticism on AI monetization in recent analyst commentary, a reminder that “AI” headlines do not always translate into near-term revenue. Barron’s

Next up for the broader tape is U.S. labor-market data — the Employment Situation report for December is due Friday, Jan. 9, at 8:30 a.m. ET — a release that often resets bets on Fed policy and moves rate-sensitive stocks such as software.

Stock Market Today

  • Sharda Cropchem Earnings Reveal Weak Cash Flow Despite Profit Growth
    May 20, 2026, 9:35 PM EDT. Sharda Cropchem Limited's (NSE:SHARDACROP) recent earnings report shows a statutory profit of ₹6.81 billion for the year ending March 2026, but free cash flow was significantly lower at ₹1.6 billion, resulting in a high accrual ratio of 0.23. This suggests the company's cash conversion is less than ideal, raising concerns about the sustainability of its earnings. Despite this, Sharda Cropchem's earnings per share (EPS) has grown impressively over the past three years. Investors remain cautious due to three warning signs surrounding the stock, with one marked as significant. The gap between profit and cash flow indicates that reported profits may overstate the company's underlying earning power.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Vertiv stock (VRT) whipsaws after Nvidia CES cooling claim; earnings next in focus
Previous Story

Vertiv stock (VRT) whipsaws after Nvidia CES cooling claim; earnings next in focus

Cipla share price slides after USFDA flags Pharmathen: what the Form 483 says
Next Story

Cipla share price slides after USFDA flags Pharmathen: what the Form 483 says

Go toTop